申联生物股价大幅波动 此前4日斩获3个涨停板

Core Viewpoint - The stock price of Shunlian Bio (688098) experienced significant fluctuations, dropping approximately 12% after previously achieving three consecutive limit-up days, indicating market volatility and investor sentiment concerns [1][2] Group 1: Company Operations - The company stated that its daily operations are normal, with no significant changes in market environment or industry policies, and no major fluctuations in product R&D, production, and sales [1] - The company is focusing on the innovative drug business, having invested 60 million yuan in its subsidiary, Shanghai Bentianc Bio-pharmaceutical Co., Ltd., acquiring a 20.48% stake in Shizhi Yuan, which is involved in the development of innovative human drugs [1] Group 2: Innovative Drug Pipeline - Shizhi Yuan has three innovative drug pipelines at different stages of development, with UB-221 currently in Phase II clinical trials in mainland China, while UB-421 and UB-621 will have their clinical strategies adjusted based on global data [2] - The success of the clinical trials for these innovative drugs remains uncertain, and the company has not identified any other media reports or market rumors that could significantly impact its stock price [2] Group 3: Business Focus and Risks - The company's main business is veterinary biological products, while the innovative drug development is independently operated by the joint venture Shizhi Yuan [2] - The innovative drug R&D process is characterized by long cycles, high investment, and significant risks, with potential impacts on clinical research outcomes and uncertainties regarding regulatory approvals [2]